ketamine has been researched along with Cocaine Abuse in 15 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to assess schizophrenia proneness and neurocognitive function in individuals dependent upon ketamine, cannabis and cocaine." | 7.78 | Neurocognitive function and schizophrenia-proneness in individuals dependent on ketamine, on high potency cannabis ('skunk') or on cocaine. ( Curran, HV; Duffin, S; Hunt, S; Mason, O; Monaghan, L; Morgan, CJ, 2012) |
| " We found that ketamine leads to significantly greater acute mystical-type effects (by Hood Mysticism Scale: HMS), dissociation (by Clinician Administered Dissociative States Scale: CADSS), and near-death experience phenomena (by the Near-Death Experience Scale: NDES), relative to the active control midazolam." | 5.27 | A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. ( Dakwar, E; Foltin, RW; Hart, CL; Hu, MC; Levin, FR; Nunes, EV, 2018) |
| " The mechanism of action analysis revealed that ketamine directly targets multiple CUD-associated genes (BDNF, CNR1, DRD2, GABRA2, GABRB3, GAD1, OPRK1, OPRM1, SLC6A3, SLC6A4) and pathways implicated in neuroactive ligand-receptor interaction, cAMP signaling and cocaine abuse/dependence." | 4.31 | Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses. ( Davis, PB; Gao, Z; Ghitza, UE; Gorenflo, M; Kaelber, DC; Winhusen, TJ; Xu, R, 2023) |
| "The aim of this study was to assess schizophrenia proneness and neurocognitive function in individuals dependent upon ketamine, cannabis and cocaine." | 3.78 | Neurocognitive function and schizophrenia-proneness in individuals dependent on ketamine, on high potency cannabis ('skunk') or on cocaine. ( Curran, HV; Duffin, S; Hunt, S; Mason, O; Monaghan, L; Morgan, CJ, 2012) |
| "The ketamine group was 53% less likely (hazard ratio=0." | 2.90 | A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. ( Basaraba, CN; Carpenter, KM; Choi, CJJ; Dakwar, E; Foltin, RW; Hart, CL; Levin, FR; Mathew, SJ; Nunes, EV; Pavlicova, M, 2019) |
| "Problematic compounds may cause seizures either acutely or on withdrawal: Their use may reduce effectiveness of antiepileptic drugs, or may simply promote and enhance chaotic lifestyles." | 2.48 | Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention. ( Borland, W; Leach, JP; Mohanraj, R, 2012) |
| "Ketamine treatment attenuated the effects of cocaine on both global and fronto-striatal FC in drug-naïve/abstinent subjects." | 1.51 | Effects of ketamine treatment on cocaine-induced reinstatement and disruption of functional connectivity in unanesthetized rhesus monkeys. ( Gopinath, KS; Howell, LL; Maltbie, EA, 2019) |
| "The growing social problem of drug abuse has increased the likelihood that anesthesiologists will find acute or chronic drug users among patients requiring anesthesia for elective or emergency surgery." | 1.37 | [Anesthesia in drug addiction]. ( Uña Orejón, R; Vázquez Moyano, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 13 (86.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Z | 1 |
| Winhusen, TJ | 1 |
| Gorenflo, M | 1 |
| Ghitza, UE | 1 |
| Davis, PB | 1 |
| Kaelber, DC | 1 |
| Xu, R | 1 |
| Brady, KT | 1 |
| Zanettini, C | 1 |
| Wilkinson, DS | 1 |
| Katz, JL | 1 |
| Dakwar, E | 5 |
| Nunes, EV | 5 |
| Hart, CL | 5 |
| Hu, MC | 1 |
| Foltin, RW | 4 |
| Levin, FR | 4 |
| Maltbie, EA | 1 |
| Gopinath, KS | 1 |
| Howell, LL | 1 |
| Mathew, SJ | 2 |
| Carpenter, KM | 1 |
| Choi, CJJ | 1 |
| Basaraba, CN | 1 |
| Pavlicova, M | 1 |
| Levin, F | 1 |
| Anerella, C | 1 |
| Uosukainen, H | 1 |
| Tacke, U | 1 |
| Winstock, AR | 1 |
| Vázquez Moyano, M | 1 |
| Uña Orejón, R | 1 |
| Morgan, CJ | 1 |
| Duffin, S | 1 |
| Hunt, S | 1 |
| Monaghan, L | 1 |
| Mason, O | 1 |
| Curran, HV | 1 |
| Wood, DM | 1 |
| Greene, SL | 1 |
| Dargan, PI | 1 |
| Leach, JP | 1 |
| Mohanraj, R | 1 |
| Borland, W | 1 |
| Parsons, JT | 1 |
| Kelly, BC | 1 |
| Wells, BE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01535937] | Phase 1/Phase 2 | 55 participants (Actual) | Interventional | 2012-02-29 | Terminated (stopped due to An analysis demonstrated that running the final participants was unnecessary.) | ||
| Using the Behaviour Change Technique Taxonomy v1 to Conceptualize the Clinical Content of a Preliminary Randomised Controlled Study of an Online Mindfulness-based Cognitive Intervention for Chemsex[NCT05929040] | 29 participants (Actual) | Interventional | 2022-03-05 | Completed | |||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| The Effect of Ketamine on Reducing Cue Reactivity in Cocaine Users[NCT01790490] | Phase 2 | 8 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Abstinence is defined as 2 or greater weeks of no cocaine use, as ascertained by the TLFB and urine toxicology. (NCT01535937)
Timeframe: Abstinence will be assessed over 4 weeks starting at the last day of week 1 and continuing through the end of study at the last day of week 5
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 13 |
| Midazolam | 3 |
Number of participants who use cocaine and drop from study. During phase 2, patients will be assessed twice weekly by TLFB and urine toxicology for cocaine use. The day of first use will determine the length of time that transpired from discharge to the first lapse onto cocaine. (NCT01535937)
Timeframe: Over the four week period following discharge from the inpatient unit at Day 5
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 16 |
| Midazolam | 26 |
Serial visual analogue scale (VAS) scores for craving elicited by cocaine cue: units on a scale (0-200), high is worse. Scores are obtained at baseline and at 24 hours after the infusion. (NCT01790490)
Timeframe: Baseline and 24 hours after infusion
| Intervention | units on a scale (0-200), high is worse (Median) |
|---|---|
| Ketamine Infusion 0.41 mg/kg Over 52 Minutes (K1) | 126 |
| Ketamine Infusion 0.71 mg/kg Over 52 Minutes (K2) | 18 |
| Lorazepam Infusion 2 mg/kg Over 52 Minutes (LZP) | 16 |
Motivation score obtained from the University of Rhode Island Change Assessment (URICA). Scores are obtained at baseline and at 24 hours after each infusion. The scores are 0-13, with higher scores indicating greater motivation. The analysis is within-subject. Scores included below are means; higher scores represent higher motivation to quit than do lower scores. (NCT01790490)
Timeframe: Baseline and 24 hours post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine Infusion 0.41 mg/kg Over 52 Minutes (K1) | 4.35 |
| Lorazepam Infusion 2 mg/kg Over 52 Minutes (LZP) | 3.2 |
| Lorazepam Infusion 2 mg/kg Over 52 Minutes (LZP) Following K1 | 4.2 |
1 review available for ketamine and Cocaine Abuse
| Article | Year |
|---|---|
Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention.
Topics: Alcohol Drinking; Alcohol Withdrawal Seizures; Alcoholism; Amphetamine-Related Disorders; Benzodiaze | 2012 |
5 trials available for ketamine and Cocaine Abuse
| Article | Year |
|---|---|
A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.
Topics: Cocaine-Related Disorders; Dissociative Disorders; Female; Hallucinogens; Hospitalization; Humans; K | 2018 |
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.
Topics: Cocaine-Related Disorders; Combined Modality Therapy; Excitatory Amino Acid Antagonists; Female; Hum | 2019 |
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.
Topics: Cocaine-Related Disorders; Combined Modality Therapy; Excitatory Amino Acid Antagonists; Female; Hum | 2019 |
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.
Topics: Cocaine-Related Disorders; Combined Modality Therapy; Excitatory Amino Acid Antagonists; Female; Hum | 2019 |
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.
Topics: Cocaine-Related Disorders; Combined Modality Therapy; Excitatory Amino Acid Antagonists; Female; Hum | 2019 |
The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.
Topics: Adult; Behavior, Addictive; Cocaine-Related Disorders; Craving; Cross-Over Studies; Cues; Dose-Respo | 2014 |
The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.
Topics: Adult; Behavior, Addictive; Cocaine-Related Disorders; Craving; Cross-Over Studies; Cues; Dose-Respo | 2014 |
The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.
Topics: Adult; Behavior, Addictive; Cocaine-Related Disorders; Craving; Cross-Over Studies; Cues; Dose-Respo | 2014 |
The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.
Topics: Adult; Behavior, Addictive; Cocaine-Related Disorders; Craving; Cross-Over Studies; Cues; Dose-Respo | 2014 |
Therapeutic infusions of ketamine: do the psychoactive effects matter?
Topics: Adult; Anesthetics, Dissociative; Cocaine-Related Disorders; Crack Cocaine; Cues; Data Interpretatio | 2014 |
Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial.
Topics: Adult; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Craving; Cross-Over St | 2017 |
9 other studies available for ketamine and Cocaine Abuse
| Article | Year |
|---|---|
Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses.
Topics: Antidepressive Agents; Artificial Intelligence; Cocaine; Cocaine-Related Disorders; Drug Repositioni | 2023 |
Searching for Treatments for Cocaine Use Disorder: The Quest Continues.
Topics: Cocaine; Cocaine-Related Disorders; Humans; Ketamine; Mindfulness; Substance-Related Disorders | 2019 |
Behavioral economic analysis of the effects of N-substituted benztropine analogs on cocaine self-administration in rats.
Topics: Animals; Behavior, Animal; Benztropine; Cocaine-Related Disorders; Dopamine Uptake Inhibitors; Econo | 2018 |
Effects of ketamine treatment on cocaine-induced reinstatement and disruption of functional connectivity in unanesthetized rhesus monkeys.
Topics: Anesthetics, Dissociative; Animals; Cocaine; Cocaine-Related Disorders; Corpus Striatum; Extinction, | 2019 |
Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Cocaine-Related Disorders; Cross-Sectional Studies | 2015 |
[Anesthesia in drug addiction].
Topics: Anesthesia; Cannabinoids; Cocaine-Related Disorders; Hallucinogens; Humans; Ketamine; Opioid-Related | 2011 |
Neurocognitive function and schizophrenia-proneness in individuals dependent on ketamine, on high potency cannabis ('skunk') or on cocaine.
Topics: Adolescent; Adult; Attention; Case-Control Studies; Cocaine-Related Disorders; Cognition Disorders; | 2012 |
Five-year trends in self-reported recreational drugs associated with presentation to a UK emergency department with suspected drug-related toxicity.
Topics: Amphetamine-Related Disorders; Cocaine-Related Disorders; Drug-Related Side Effects and Adverse Reac | 2013 |
Differences in club drug use between heterosexual and lesbian/bisexual females.
Topics: Adolescent; Adult; Age Factors; Amphetamine-Related Disorders; Bisexuality; Cocaine-Related Disorder | 2006 |